Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC- ...
The patent, when formally approved, will reinforce protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added ...
Many medications that are commonly referred to as “weight loss drugs” are not actually FDA-approved for this purpose. One of the most popular—Ozempic—is a type 2 diabetes drug that’s often prescribed ...